Key result
Etomidate for anesthesia induction resulted in similar outcomes for mortality and length of hospital stay compared to other drugs in patients undergoing major cardiac surgery.
Why the study?
Does etomidate for anesthesia induction improve or worsen clinical outcomes in patients ahead of major cardiac surgery?
Does etomidate for anesthesia induction improve or worsen clinical outcomes in patients ahead of major cardiac surgery?
Answers are grounded in this paper and cite their sources.
Etomidate appears to be a safe and hemodynamically stable option for anesthesia induction in major cardiac surgery, with no evidence of worse clinical outcomes compared to other agents despite concerns regarding transient adrenal suppression.
Use of etomidate for anesthesia induction is still debated. In the previous issue of Critical Care, Heinrich and colleagues reported that etomidate for anesthesia induction had similar outcome in comparison with other drugs, in a specific population of 3,054 patients ahead of major cardiac surgery. For the authors, the similar outcomes for mortality and length of hospital stay add to the hemodynamic stability and the improved intubation conditions to support keeping etomidate in the emergency drugs armamentarium for induction of anesthesia in patients at risk of hemodynamic failure. This commentary reviews the results and implications of their study.
No takes yet. Share an insight, caveat, or question.
Jong et al. (2014) conducted an editorial in Major cardiac surgery (n=3,054). Etomidate vs. Other anesthesia induction drugs was evaluated on Mortality and length of hospital stay. Etomidate for anesthesia induction resulted in similar outcomes for mortality and length of hospital stay compared to other drugs in patients undergoing major cardiac surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: